A Common Gene Variant in the Opioid Receptor Dramatically Weakens Pain Signaling
The N40D polymorphism in the human mu-opioid receptor (found in ~10% of people) severely impaired receptor signaling in response to beta-endorphin, potentially explaining individual differences in pain sensitivity and opioid drug response.
Quick Facts
What This Study Found
The N40D polymorphism in the human mu-opioid receptor severely impaired beta-endorphin-stimulated G-protein coupling and downstream signaling, potentially explaining ~10% of the population's altered pain sensitivity and opioid drug response.
Key Numbers
How They Did This
In-vitro study expressing wild-type and N40D variant mu-opioid receptors in cell lines. Receptor signaling (G-protein coupling, cAMP inhibition) measured in response to beta-endorphin and other opioid ligands.
Why This Research Matters
If 10% of people have a weakened natural painkilling receptor, this has massive implications for pain management, addiction risk, and personalized medicine — their endogenous opioid system is inherently less effective.
The Bigger Picture
Pharmacogenomics — using genetic information to guide drug therapy — depends on identifying functional gene variants. This mu-opioid receptor polymorphism affects how the body's entire opioid system works, from pain perception to drug response to addiction risk.
What This Study Doesn't Tell Us
In-vitro overexpression study may not perfectly represent in-vivo receptor function. The clinical consequences of the signaling impairment need population-level validation.
Questions This Raises
- ?Do N40D carriers need different opioid doses for pain management?
- ?Does this variant increase addiction risk due to inadequate natural pain relief?
- ?Should mu-opioid receptor genotyping guide pain treatment?
Trust & Context
- Key Stat:
- 10% of people affected The N40D variant severely impairs natural opioid signaling — 1 in 10 people may have inherently weaker pain relief from their own endorphins
- Evidence Grade:
- Moderate evidence from detailed in-vitro receptor pharmacology demonstrating clear functional consequences of a common genetic variant.
- Study Age:
- Published in 2001. The OPRM1 A118G/N40D polymorphism has become one of the most studied pharmacogenomic variants, with confirmed clinical associations.
- Original Title:
- A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling.
- Published In:
- The Journal of biological chemistry, 276(5), 3130-7 (2001)
- Authors:
- Befort, K, Filliol, D, Decaillot, F M, Gaveriaux-Ruff, C, Hoehe, M R, Kieffer, B L
- Database ID:
- RPEP-00648
Evidence Hierarchy
Frequently Asked Questions
Why do some people feel more pain?
About 10% of people carry a gene variant that weakens their mu-opioid receptor's response to the body's natural painkillers. Their endogenous pain relief system is less effective, potentially making them more pain-sensitive.
Should pain treatment be based on genetics?
This study supports that idea. If your opioid receptors don't respond as well to natural painkillers, you might need different pain management strategies. Genetic testing for this variant is increasingly available.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00648APA
Befort, K; Filliol, D; Decaillot, F M; Gaveriaux-Ruff, C; Hoehe, M R; Kieffer, B L. (2001). A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling.. The Journal of biological chemistry, 276(5), 3130-7.
MLA
Befort, K, et al. "A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling.." The Journal of biological chemistry, 2001.
RethinkPeptides
RethinkPeptides Research Database. "A single nucleotide polymorphic mutation in the human mu-opi..." RPEP-00648. Retrieved from https://rethinkpeptides.com/research/befort-2001-a-single-nucleotide-polymorphic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.